PerkinElmer, Inc. (Waltham, MA, USA), a global analytical services and solutions provider has acquired Covaris (Woburn, MA, USA), a developer of solutions to empower life science innovations. The merger will boost Covaris’ growth potential and expand PerkinElmer’s current life sciences portfolio into the high-growth diagnostics end market.
With precision medicine gaining traction for personalized disease treatment and prevention, Covaris is well-positioned to help enable and accelerate the next generation of life sciences innovation, especially through its Next-Generation Sequencing (NGS) capability, for efficient, reproducible, and high-throughput sample preparation and data analysis. Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis, including instruments, consumables, and reagents. Covaris’ solutions empower customers to accelerate the pace of research and drug discovery for clinical diagnostics, biopharma, and research markets globally.
“Covaris has a well-defined growth strategy with market-leading technologies and a very capable leadership team that will allow PerkinElmer to deepen its life sciences portfolio in the diagnostics end market,” said Dirk Bontridder, CEO of PerkinElmer. “We see significant growth opportunities resulting from the combined resources of both companies, with PerkinElmer’s global scale unlocking commercial opportunities for Covaris.”
“We are excited to begin our new chapter as part of PerkinElmer, an exceptional brand that resonates in our core markets, and will allow us to bring our technology to more customers and expand our growth globally,” added Annemarie Watson, CEO of Covaris. “Our two cultures are very similar and both our customers as well as our employees will benefit from strong R&D resources and complementary solution capabilities.”
Related Links:
PerkinElmer, Inc.
Covaris
